Personalis' Cancer Monitoring Tool Shows Early Detection of Relapse

MT Newswires Live06-02

Personalis' (PSNL) ultrasensitive minimal residual disease detection with NeXT Personal showed early detection of patients at risk for relapse across six solid tumor types, the company said Tuesday.

The tool successfully identified all instances of colorectal cancer relapse before clinical imaging and detected 82% of future relapses four weeks after surgery, the company said.

NeXT Personal also consistently identified genetic tumor material at extremely low levels in lung cancer patients, predicting a higher risk of disease return, it said.

Additional studies covering ovarian and endometrial cancers, melanoma, and renal cell carcinoma indicated that the test can forecast treatment responses and potential relapses, Personalis said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment